Dianthus Therapeutics, Inc.
DNTH
$16.86
-$0.585-3.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -100.73M | -84.97M | -67.09M | -56.68M | -50.21M |
| Total Depreciation and Amortization | 438.00K | 412.00K | 437.00K | 372.00K | 381.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.62M | 6.73M | 5.59M | 5.28M | 2.82M |
| Change in Net Operating Assets | 803.00K | -351.00K | -1.52M | -286.00K | 5.50M |
| Cash from Operations | -90.87M | -78.18M | -62.59M | -51.32M | -41.52M |
| Capital Expenditure | -97.00K | -105.00K | -84.00K | -124.00K | -128.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -266.41M | -286.71M | -271.86M | -23.96M | -3.26M |
| Cash from Investing | -266.51M | -286.81M | -271.94M | -24.08M | -3.39M |
| Total Debt Issued | -- | -- | 0.00 | 0.00 | 0.00 |
| Total Debt Repaid | -- | -- | 0.00 | 0.00 | 0.00 |
| Issuance of Common Stock | 40.18M | 270.29M | 230.61M | 230.32M | 230.27M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.24M | -14.67M | -19.53M | 118.90M | 121.15M |
| Cash from Financing | 37.94M | 255.62M | 211.08M | 349.23M | 351.42M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -319.44M | -109.37M | -123.45M | 273.83M | 306.52M |